论文期刊

取消

高级检索

检索历史清除

首页> Breast cancer research and treatment> The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.

The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.

导出原文传递

翻译打印收藏纠错

作者： Hyung Suk,Kim ^[1] ; Tae Kyung,Yoo ^[2] ; Woo Chan,Park ^[2] ; Byung Joo,Chae ^[3]

作者单位： Division of Breast Surgery, Department of Surgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea. ^[1] Division of Breast Surgery, Department of Surgery, Seoul St. Mary's Hospital, The Catholic University of Medicine, Seoul, Korea. ^[2] Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, Korea. bjchae@gmail.com. ^[3]

关键词 Breast neoplasm HER2 positive Mucinous carcinoma Prognosis Trastuzumab

主题词腺癌, 黏液(Adenocarcinoma, Mucinous);乳腺肿瘤(Breast Neoplasms);化学疗法, 辅助(Chemotherapy, Adjuvant);雌激素受体α(Estrogen Receptor alpha);女(雌)性(Female);人类(Humans);中年人(Middle Aged);预后(Prognosis);受体, 孕酮(Receptors, Progesterone);韩国(Republic of Korea);学会, 医学(Societies, Medical);存活率(Survival Rate)

DOI 10.1007/s10549-020-05550-4

PMID 32020434

发布时间 2024-07-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Breast cancer research and treatment

Breast cancer research and treatment

2020年180卷2期

461-470页

相似文献

中文期刊
外文期刊
学位论文
会议论文

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷